Gefitinib (Gef), a tyrosine kinase inhibitor (TKI) associated with anti‐epidermal growth factor receptor (EGFR) therapy, has been approved as the first‐line therapy for EGFR‐mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.